Prediction of cardiovascular events by central blood pressure using radial tonometry in type 2 diabetes mellitus patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: High blood pressure (BP) and type 2 diabetes mellitus (T2DM) are major causes of atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF). Central blood pressure (CBP) is more predictive of ASCVD than is brachial BP; however, an association of CBP with ASCVD has not been found in T2DM patients. We evaluated the impact of CBP and the association between optimal level of noninvasively measured CBP and office BP in T2DM patients based on composite outcome of ASCVD, HF, and complications of hypertension. Methods: Patients were enrolled from June 2011 to December 2015 and were followed up through December 2019. CBP was measured using radial tonometry. The primary endpoints were composite outcome of ASCVD, HF, and hypertension-induced complications such as left ventricular hypertrophy, retinopathy, and proteinuria. Results: During the 6.5-year follow-up period, 515 patients were enrolled in the study. A total of 92 patients (17.9%) developed primary endpoints. The mean age of subjects was 61.3 ± 12.1 years and 55% (n = 283) were male. Patients who developed primary endpoints were older (65.3 ± 9.5 years vs. 60.5 ± 12.4 years) and had lower high-density lipoprotein (36.6 ± 9.4 mg/dL vs. 41.8 ± 11.1 mg/dL), higher CBP (123.6 ± 20.6 mmHg vs. 118.0 ± 20.6 mmHg), and higher pulse pressure (61.3 ± 16.6 mmHg vs. 56.5 ± 15.1 mmHg) than subjects without primary endpoint development. After adjustment for various risk factors, CBP was an independent predictor for primary endpoints (hazard ratio, 1.14; 95% confidence interval, 1.02-1.27; P = 0.016). In addition, the association of CBP and primary endpoints showed a U-shaped curve with the lowest incidence at CBP 118 mmHg and systolic BP about 128 mmHg. Conclusions: We show the importance of CBP measurements in T2DM patients and present a cutoff value for ASCVD events and hypertension-induced complications.
Abstract
Background: High blood pressure (BP) and type 2 diabetes mellitus (T2DM) are major causes of atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF). Central blood pressure (CBP) is more predictive of ASCVD than is brachial BP; however, an association of CBP with ASCVD has not been found in T2DM patients. We evaluated the impact of CBP and the association between optimal level of noninvasively measured CBP and office BP in T2DM patients based on composite outcome of ASCVD, HF, and complications of hypertension. Methods: Patients were enrolled from June 2011 to December 2015 and were followed up through December 2019. CBP was measured using radial tonometry. The primary endpoints were composite outcome of ASCVD, HF, and hypertension-induced complications such as left ventricular hypertrophy, retinopathy, and proteinuria. Results: During the 6.5-year follow-up period, 515 patients were enrolled in the study. A total of 92 patients (17.9%) developed primary endpoints. The mean age of subjects was 61.3 ± 12.1 years and 55% (n = 283) were male. Patients who developed primary endpoints were older (65.3 ± 9.5 years vs. 60.5 ± 12.4 years) and had lower high-density lipoprotein (36.6 ± 9.4 mg/dL vs. 41.8 ± 11.1 mg/dL), higher CBP (123.6 ± 20.6 mmHg vs. 118.0 ± 20.6 mmHg), and higher pulse pressure (61.3 ± 16.6 mmHg vs. 56.5 ± 15.1 mmHg) than subjects without primary endpoint development. After adjustment for various risk factors, CBP was an independent predictor for primary endpoints (hazard ratio, 1.14; 95% confidence interval, 1.02-1.27; P = 0.016). In addition, the association of CBP and primary endpoints showed a U-shaped curve with the lowest incidence at CBP 118 mmHg and systolic BP about 128 mmHg. Conclusions: We show the importance of CBP measurements in T2DM patients and present a cutoff value for ASCVD events and hypertension-induced complications.
참고문헌 (25)
- NCD Risk Factor Collaboration(NCD-RisC), "Worldwide trends in hypertension prevalence and progress in treatment and control from. to 2019:a pooled analysis of 1201 population-representative studies with 104million participants", Lancet, 2021(398), pp.957~980 (1990)
- Burke AP, "Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death", Circulation, 94, pp.3138~3145 (1996)
- Bombelli M, "Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values", J Hypertens, 27, pp.2458~2464 (2009)
- Levy D, "Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study", N Engl J Med, 322, pp.1561~1566 (1990)
- Climie RE, "Centralto-brachial blood pressure amplification in type 2 diabetes : a systematic review and meta-analysis", J Hum Hypertens, 33, pp.94~105 (2019)
- Lewington S, "Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61prospective studies", Lancet, 360, pp.1903~1913 (2002)
- Patel A, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus(the ADVANCE trial) : a randomised controlled trial", Lancet, 370, pp.829~840 (2007)
- Sundström J, "Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes : cohort study of 34 009 primary care patients", J Hypertens, 31, pp.1603~1610 (2013)
- American Diabetes Association, "10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021", Diabetes Care, 44(Suppl 1), pp.S125~S150 (2021)
- Pickering TG, "Recommendations for blood pressure measurement in humans and experimental animals : part 1 : blood pressure measurement in humans : a statement for professionals from the subcommittee of professional and public education of the American heart association council on high blood pressure research", Hypertension, 45(1), pp.142~161 (2005)
- Cheng HM, "Central blood pressure for the management of hypertension: is it a practical clinical tool in current practice?", J Clin Hypertens(Greenwich), 22, pp.391~406 (2020)
- Hae-Young Lee, "2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension", Clinical Hypertension, 25(4), pp.51~74 (2019), 대한고혈압학회[DOI]
- Ohte N, "Relationship between blood pressure obtained from the upper arm with a cuff-type sphygmomanometer and central blood pressure measured with a catheter-tipped micromanometer", Heart Vessels, 22, pp.410~415 (2007)
- McEniery CM, "Normal vascular aging : differential effects on wave reflection and aortic pulse wave velocity : the Anglo-CardiffCollaborative Trial(ACCT)", J Am Coll Cardiol, 46, pp.1753~1760 (2005)
- Albaladejo P, "Heart rate, arterial stiffness, and wave reflections in paced patients", Hypertension, 38, pp.949~952 (2001)
- Kim G, "The clinical usefulness of central hemodynamics to evaluate diastolic dysfunction in subjects without hypertension", Clin Interv Aging, 9, pp.527~533 (2014)
- Fryar CD, "Hypertension prevalence and control among adults : United States, 2015–2016", NCHS Data Brief, 289, pp.1~8 (2017)
- Lamarche F, "Prediction of cardiovascular events by type I central systolic blood pressure : a prospective study", Hypertension, 77, pp.319~327 (2021)
- Sharman JE, "Left ventricular mass in patients with type 2 diabetes is independently associated with central but not peripheral pulse pressure", Diabetes Care, 28, pp.937~939 (2005)
- Hashimoto J, "Aortic stiffness determines diastolic blood flow reversal in the descending thoracic aorta : potential implication for retrograde embolic stroke in hypertension", Hypertension, 62, pp.542~549 (2013)
- Hegab Z, "Role of advanced glycation end products in cardiovascular disease", World J Cardiol, 4, pp.90~102 (2012)
- Vergnaud AC, "Pulse pressure amplification, adiposity and metabolic syndrome in subjects under chronic antihypertensive therapy : the role of heart rate", Atherosclerosis, 199, pp.222~229 (2008)
- Lee HY, "Aging and arterial stiffness", Circ J, 74, pp.2257~2262 (2010)
- Iorga A, "The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy", Biol Sex Differ, 8, pp.33~ (2017)
- Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the women’s health initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)